Imaging and therapeutic targeting of oncogenic marks in lymphoproliferative malignancies (C03)

• Subject Area: Nuclear Medicine, Radiotherapy, Radiobiology ; Hematology, Oncology
• Term: from 2009 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618

Elevated c-Myc (Myc) and CXCR4 expression are characteristics of aggressive cancers and associated with dissemination, treatment resistance, stemness and poor prognosis. We have developed imaging-guided therapies directed against CXCR4 and identified synthetic lethality approaches targeting the Myc phenotype. Using human xenograft and genetically-modified mouse models of lymphoma we will further develop CXCR4 theranostics, investigate novel imaging applications, and perform mechanistic studies. An in vivo cancer gene screen will be exploited for identifying novel synthetic lethal Myc interaction partners and pathways suitable for combined imaging-therapy approaches.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies
• Applicant Institution: Technische Universität München (TUM)
• Project Heads: Professor Dr. Ambros Beer, until 1/2014; Professor Dr. Ulrich Keller